This announcement appears as a matter of record only

Milkhaus Laboratories

received $5,000,000 for
Phase 2 clinical trials from
 

Current Shareholders

FOCUS Regional Managing Partner William S. Lear assisted in the negotiations as the representative of Milkhaus Laboratories.